USD21.69
✓ The FDA has repeatedly flagged AOD-9604 as a compound of concern. It was placed on the Category 2 list in 2023 — bulk drug substances in compounding that may present significant https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12967-024-05768-6/MediaObjects/12967_2024_5768_Fig4_HTML.png Select your plan & weekly dose:30-Day · 13mg · $459 The original metabolic characterisation of the synthetic fragment was reported by Ng and colleagues ( Hormone Research , 2000), and Heffernan and colleagues ( Endocrinology , 2001) used β3-adrenergic-receptor knock-out models to probe the pathway implicated in the fragment’s lipid-metabolic signalling — the reason the β3-adrenergic receptor is referenced across AOD-9604 research literature ghk-cu
USD21.69
USD27.65
USD24.74
Check whether the record lists an action still required from you. Use current seller information instead of an unrelated third-party estimate.
Ask how the seller plans to complete the existing arrangement. Keep the unresolved request tied to the original purchase details.
Do not assume a new listing automatically changes your recorded order. Avoid guessing why the seller changed the public listing.